跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

1491300

USP

催产素

United States Pharmacopeia (USP) Reference Standard

别名:

垂体后叶提取物, α-多巴胺, 催产激素

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C43H66N12O12S2
CAS号:
50-56-6
分子量:
1007.19
Beilstein:
3586108
MDL號碼:
MFCD00076731
分類程式碼代碼:
41116107
PubChem物質ID:
329750651
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

oxytocin

製造商／商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

[H]N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)[C@@H](C)CC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O

InChI

1S/C43H66N12O12S2/c1-5-22(4)35-42(66)49-26(12-13-32(45)57)38(62)51-29(17-33(46)58)39(63)53-30(20-69-68-19-25(44)36(60)50-28(40(64)54-35)16-23-8-10-24(56)11-9-23)43(67)55-14-6-7-31(55)41(65)52-27(15-21(2)3)37(61)48-18-34(47)59/h8-11,21-22,25-31,35,56H,5-7,12-20,44H2,1-4H3,(H2,45,57)(H2,46,58)(H2,47,59)(H,48,61)(H,49,66)(H,50,60)(H,51,62)(H,52,65)(H,53,63)(H,54,64)/t22-,25-,26-,27-,28-,29-,30-,31-,35-/m0/s1

InChI 密鑰

XNOPRXBHLZRZKH-DSZYJQQASA-N

基因資訊

human ... OXTR(5021)

正在寻找类似产品? 访问 产品对比指南

相关类别

Amino Acid Sequence

Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 [Disulfide Bridge: 1-6]

一般說明

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。

催产素是一种九肽激素，具有诱导子宫平滑肌和乳腺肌上皮细胞收缩的能力。这种激素通过合成生产，最低催产素活性为每毫克400 USP催产素单位。

應用

Oxytocin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Oxytocin Injection

生化／生理作用

刺激子宫收缩和哺乳；增加Na+ 排泄；刺激子宫肌层GTP酶和磷脂酶 C。

分析報告

这些产品仅供测试和分析使用。它们不适用于人类或动物的给药，不可用于诊断、治疗或治愈任何疾病。

其他說明

该产品是美国药典生物制品计划的一部分。
可能适用相应的销售限制。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Elizabeth C Finger et al.
Neurology, 84(2), 174-181 (2014-12-17)
To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible
Yuta Aoki et al.
Brain : a journal of neurology, 137(Pt 11), 3073-3086 (2014-08-26)
Recent studies have suggested oxytocin's therapeutic effects on deficits in social communication and interaction in autism spectrum disorder through improvement of emotion recognition with direct emotional cues, such as facial expression and voice prosody. Although difficulty in understanding of others'
Mikko J Peltola et al.
Emotion (Washington, D.C.), 14(3), 469-477 (2014-04-23)
Recent studies suggest that parental caregiving is associated with adaptive changes in neurocognitive responses to emotional cues and oxytocin function, possibly reflecting the increased need of parents to monitor infants' emotional states. In the current study, we investigated whether the
Elliot C Brown et al.
Psychiatry research, 219(3), 436-442 (2014-07-23)
Patients with schizophrenia suffer from dysfunctional social behaviour. Social approach and avoidance (AA) has been associated with motor responses, as the affective valence and gaze direction of facial stimuli can bias push and pull motor tendencies. The aim of this
Y Aoki et al.
Molecular psychiatry, 20(4), 447-453 (2014-07-30)
The neuropeptide oxytocin may be an effective therapeutic strategy for the currently untreatable social and communication deficits associated with autism. Our recent paper reported that oxytocin mitigated autistic behavioral deficits through the restoration of activity in the ventromedial prefrontal cortex
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门